Week of April 15, 2019 | Vol. 8, Issue 15
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
Regeneron and Alnylam Ink $1 Billion Eye and Central Nervous System R&D Deal
Regeneron Pharmaceuticals and Alnylam Pharmaceuticals announced a collaboration deal to discover, develop and commercialize treatments for the eye and central nervous system
Under the terms of the agreement, Regeneron is paying $400 million upfront to Alnylam and acquiring another $400 million in equity at a price per share of $90, or 4.44 million common shares. Alnylam will be eligible for up to another $200 million in milestone payments during early clinical development for the eye and CNS programs. Alnylam plans to work exclusively with Regeneron to discover RNAi therapeutics for the two primary indications, eye and CNS diseases. Regeneron will lead development and marketing for programs that target the eye and Alnylam will be eligible for milestone payments and royalties. The two companies will work together to advance and alternate heading the CNS programs, with the lead group holding global development and commercial responsibility. For CNS programs, both companies will be able to participate equally in the other’s programs at the point of candidate selection. Regeneron and Alnylam indicate they plan to advance programs directed to 30 targets, with many of them being advanced into clinical development during the initial five-year discovery period. That also includes an option to extend the partnership.

 C ontinue Reading at BioSpace
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
12 transactions totaling $97 million
Supplies, Equipment & Services
19 transactions totaling $17 million
Healthcare IT & Managed Care
3 transactions
Healthcare Facilities & Distributors
9 transactions totaling $68 million
Pharma & Biotech
30 transactions totaling $640 million
Supplies, Equipment & Services
17 transactions totaling $128 million
Healthcare IT & Managed Care
11 transactions totaling $27 million
Healthcare Facilities & Distributors
4 transactions totaling $9 million
Pharma & Biotech
23 transactions totaling $892 million
Supplies, Equipment & Services
6 transactions totaling $44 million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
0 transactions
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
April 12, 2019 - BioPharma Dive
Intercept has established a big lead in developing a treatment for a medically underserved NASH field. This is a condition in which an accumulation of fat in the liver leads to fibrosis and, eventually, cirrhosis, and is believed to be growing in prevalence thanks to rising obesity rates in Western countries.

April 11, 2019 - Fierce Pharma
High-potency drugs remain in high demand, and Cambrex continues to build new facilities to capture that market. Its facility in Iowa will be ready to churn out active pharmaceutical ingredients beginning in May.The East Rutherford, New Jersey-based small molecule specialist has completed a new $24 million facility in Charles City, Iowa. The 6,000-square-foot, four-reactor facility is currently being validated, the company  said Wednesday.

April 10, 2019 -  Fierce Biotech
With a host of sites around the U.S. and increasingly around the world, Johnson & Johnson’s startup arm JLABS has opened its latest city hub in the nation’s capital. And it’s not doing it alone:  JLABS @ Washington, D.C ., as it’s called, is partnering up with the Children's National Health System, a research hospital for kids, on a 32,000-square-foot facility at the CNHS’s Innovation Campus in the city. 

April 9, 2019 -  Bio Space
LEO Pharma A/S , a global leader in medical dermatology and Elektrofi, a Boston- based biotechnology company focused on drug formulation and delivery innovations, today announced an expansion of the two companies’ partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology.
Recent Materials Providing Insight Into Healthcare Related Industries
Centene | W ellCare
March 2019
Thermo Fisher | B rammer Bio
March 2019